Back to top
more

Elanco Animal Health (ELAN)

(Delayed Data from NYSE)

$13.57 USD

13.57
4,121,639

+0.31 (2.34%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $13.56 -0.01 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (151 out of 252)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Elanco Animal Health Incorporated (ELAN) Q3 Earnings and Revenues Beat Estimates

Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 15.38% and 1.80%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Healthcare Stock Earnings Slated on Nov 6: HUM, ELAN & More

Rise in senior population, shift of care to lower-cost settings and decline in unemployment are likely to have driven healthcare sector earnings.

Earnings Preview: Elanco Animal Health Incorporated (ELAN) Q3 Earnings Expected to Decline

Elanco Animal Health Incorporated (ELAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zoetis Appoints Kristin Peck as New CEO, Alaix to Retire

Zoetis (ZTS) names executive vice president Kristin Peck as the new CEO, effective Jan 1, 2020.

Zoetis (ZTS) Receives EC Approval for Simparica Trio in Dogs

Zoetis' (ZTS) leading animal health portfolio gets a boost with the approval of Simparica Trio.

Bayer Inks $7.6B Deal to Divest Animal Health Unit to Elanco

Bayer (BAYRY) inks deal with Elanco to divest its animal health business for $7.6 billion.

Mitchell Moore headshot

Bayer Sells Animal Health Division to Elanco: Now What?

On Tuesday, Bayer (BAYRY) announced the sale of its animal-health division to American competitor Elanco (ELAN), for a net price of $7.6 billion. The deal is expected to close in mid-2020 after regulatory approval.

Lilly (LLY) Down Despite Q1 Earnings Beat on Sales View Cut

Eli Lilly's (LLY) earnings beat estimates in Q1. Stock falls in pre-market trading as the company lowers its full-year revenue forecast.

Do Options Traders Know Something About Elanco Health (ELAN) Stock We Don't?

Investors need to pay close attention to Elanco Health (ELAN) stock based on the movements in the options market lately.

Lilly to Begin Exchange Offer for Sale of Balance Elanco Stake

Eli Lilly (LLY) to initiate an exchange offer for shareholders to divest its remaining ownership interest in Elanco

Eli Lilly (LLY) Q4 Earnings Coming Up: What's in the Cards?

Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead the company to an earnings beat.

The Zacks Analyst Blog Highlights: Intuitive Surgical, Illumina, HCA, Elanco Animal and Humana

The Zacks Analyst Blog Highlights: Intuitive Surgical, Illumina, HCA, Elanco Animal and Humana

Swarup Gupta headshot

5 Great Medical Stocks to Buy Ahead of Q4 Earnings

A Reuters review of Wall Street Research firms reveals that health care is the most favored of the S&P 500's 11 major sectors.

Lilly's Shares Rise on Robust 2019 View, Dividend Hike

Eli Lilly's (LLY) shares rise 3% on an upbeat outlook for 2019. It also hikes quarterly dividend by 15%.

Lilly (LLY) Tops Q3 Earnings, Lifts 2018 Outlook, Stock Up

Eli Lilly (LLY) beats estimates for earnings but misses the same for sales. The company raises its previously issued outlook for adjusted earnings. Stock rises in pre-market trading.